What is Rigel?
Founded in 1996 and headquartered in San Francisco, California, Rigel Pharmaceuticals is a drug development company focused on discovering and developing small-molecule drugs. Its therapeutic areas of specialization include autoimmune diseases, muscle disorders, and inflammatory diseases. The company's long-standing presence in the industry and its focus on critical unmet medical needs position it as a significant player in the biopharmaceutical landscape, aiming to bring innovative treatments to patients.
How much funding has Rigel raised?
Rigel has raised a total of $888.4M across 12 funding rounds:
Stock Offering
$127.5M
Stock Offering
$101.5M
Stock Offering
$140.5M
Stock Offering
$135.7M
Stock Offering
$46M
Stock Offering
$69.7M
Stock Offering
$58.4M
Debt
$60M
Stock Issuance/Offering (2008): $127.5M backed by Undisclosed
Stock Issuance/Offering (2009): $101.5M with participation from Undisclosed
Stock Issuance/Offering (2011): $140.5M led by Undisclosed
Stock Issuance/Offering (2012): $135.7M supported by Undisclosed
Stock Issuance/Offering (2017): $46M featuring Undisclosed
Stock Issuance/Offering (2017): $69.7M backed by Undisclosed
Stock Issuance/Offering (2018): $58.4M with participation from Undisclosed
Debt (2019): $60M led by MidCap Financial
Key Investors in Rigel
MidCap Financial
MidCap Financial is a provider of flexible financing solutions, specializing in tailoring capital to meet the specific needs of companies, ensuring timely and efficient funding to support growth and operational objectives.
Novartis
Novartis is a global pharmaceutical giant headquartered in Switzerland, dedicated to developing innovative medications and healthcare solutions across a broad spectrum of therapeutic areas, with a strong emphasis on research and development.
MPM Capital
MPM BioImpact is a venture capital firm focused on early-stage investments in the life sciences sector, aiming to transform scientific discoveries into therapeutics that address critical patient needs.
What's next for Rigel?
The recent major strategic investment suggests Rigel Pharmaceuticals is poised for significant advancements in its research and development pipeline. This capital is likely to accelerate the clinical progression of its lead drug candidates and potentially expand its therapeutic reach. As a company with a history of enterprise-level funding, Rigel is well-positioned to navigate the complex and capital-intensive drug development process, aiming to translate scientific innovation into viable treatments for challenging diseases.
See full Rigel company page
